The results showed that LNP‐circUGP2 treatment upregulated circUGP2 levels and activated the p53 signaling pathway in the subcutaneous tumors (Figure S6C–E, Supporting Information), resulting in the suppression of tumor growth and the reversal of the negative impacts associated with circUGP2 knockdown (Figure 8G,H). The gene discussed is TP53; the disease is neoplasm.